PMID- 26927057
OWN - NLM
STAT- MEDLINE
DCOM- 20161108
LR  - 20200225
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 21
IP  - 3
DP  - 2016 Feb 27
TI  - 1-Deoxynojirimycin Alleviates Liver Injury and Improves Hepatic Glucose 
      Metabolism in db/db Mice.
PG  - 279
LID - 10.3390/molecules21030279 [doi]
LID - 279
AB  - The present study investigated the effect of 1-Deoxynojirimycin (DNJ) on liver 
      injury and hepatic glucose metabolism in db/db mice. Mice were divided into five 
      groups: normal control, db/db control, DNJ-20 (DNJ 20 mg.kg(-1).day(-1)), DNJ-40 
      (DNJ 40 mg.kg(-1).day(-1)) and DNJ-80 (DNJ 80 mg.kg(-1).day(-1)). All doses were 
      treated intravenously by tail vein for four weeks. DNJ was observed to 
      significantly reduce the levels of serum triglyceride (TG), total cholesterol 
      (TC), low density lipoprotein cholesterol (LDL-C) and liver TG, as well as 
      activities of serum alanine aminotransferase (ALT), and aspartate transaminase 
      (AST); DNJ also alleviated macrovesicular steatosis and decreased tumor necrosis 
      factor alpha (TNF-alpha), interleukin-1 (IL-1), interleukin-6 (IL-6) levels in liver 
      tissue. Furthermore, DNJ treatment significantly increased hepatic glycogen 
      content, the activities of hexokinase (HK), pyruvate kinase (PK) in liver tissue, 
      and decreased the activities of glucose-6-phosphatase (G6Pase), glycogen 
      phosphorylase (GP), and phosphoenolpyruvate carboxykinase (PEPCK). Moreover, DNJ 
      increased the phosphorylation of phosphatidylinositol 3 kinase (PI3K) on p85, 
      protein kinase B (PKB) on Ser473, glycogen synthase kinase 3beta (GSK-3beta) on Ser9, 
      and inhibited phosphorylation of glycogen synthase (GS) on Ser645 in liver tissue 
      of db/db mice. These results demonstrate that DNJ can increase hepatic insulin 
      sensitivity via strengthening of the insulin-stimulated PKB/GSK-3beta signal pathway 
      and by modulating glucose metabolic enzymes in db/db mice. Moreover, DNJ also can 
      improve lipid homeostasis and attenuate hepatic steatosis in db/db mice.
FAU - Liu, Qingpu
AU  - Liu Q
AD  - College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, 
      China. lqpcy1224@163.com.
FAU - Li, Xuan
AU  - Li X
AD  - College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, 
      China. xuanli@njutcm.edu.cn.
FAU - Li, Cunyu
AU  - Li C
AD  - College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, 
      China. licunyuok@163.com.
AD  - Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources 
      Industrialization, Nanjing 210023, China. licunyuok@163.com.
FAU - Zheng, Yunfeng
AU  - Zheng Y
AD  - College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, 
      China. zyunfeng88@126.com.
AD  - Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources 
      Industrialization, Nanjing 210023, China. zyunfeng88@126.com.
FAU - Wang, Fang
AU  - Wang F
AD  - College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, 
      China. wangfa8875@163.com.
FAU - Li, Hongyang
AU  - Li H
AD  - College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, 
      China. lihongyang@sina.com.
FAU - Peng, Guoping
AU  - Peng G
AD  - College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, 
      China. guopingpeng@sohu.com.
AD  - Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources 
      Industrialization, Nanjing 210023, China. guopingpeng@sohu.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160227
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Hypoglycemic Agents)
RN  - 19130-96-2 (1-Deoxynojirimycin)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - 1-Deoxynojirimycin/*administration & dosage/chemistry/pharmacology
MH  - Animals
MH  - Dose-Response Relationship, Drug
MH  - Fatty Liver/*drug therapy/metabolism
MH  - Glucose/*metabolism
MH  - Hypoglycemic Agents/*administration & dosage/pharmacology
MH  - Injections, Intravenous
MH  - Insulin Resistance
MH  - Lipid Metabolism/drug effects
MH  - Liver/*metabolism
MH  - Male
MH  - Mice
MH  - Mice, Transgenic
MH  - Molecular Structure
MH  - Signal Transduction/drug effects
PMC - PMC6274115
OTO - NOTNLM
OT  - 1-Deoxynojirimycin
OT  - PKB/GSK-3beta
OT  - db/db mice
OT  - glucose metabolic enzymes
OT  - hepatic glucose metabolism
OT  - hepatic glycogen
OT  - hepatic insulin sensitivity
OT  - lipid metabolism
OT  - liver
COIS- The authors declare no conflict of interest.
EDAT- 2016/03/02 06:00
MHDA- 2016/11/09 06:00
PMCR- 2016/02/27
CRDT- 2016/03/02 06:00
PHST- 2016/01/03 00:00 [received]
PHST- 2016/02/21 00:00 [revised]
PHST- 2016/02/23 00:00 [accepted]
PHST- 2016/03/02 06:00 [entrez]
PHST- 2016/03/02 06:00 [pubmed]
PHST- 2016/11/09 06:00 [medline]
PHST- 2016/02/27 00:00 [pmc-release]
AID - molecules21030279 [pii]
AID - molecules-21-00279 [pii]
AID - 10.3390/molecules21030279 [doi]
PST - epublish
SO  - Molecules. 2016 Feb 27;21(3):279. doi: 10.3390/molecules21030279.